Provectus Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative immunotherapy medicines utilizing a proprietary class of small molecules known as halogenated xanthenes. Their lead compound, rose bengal disodium, is being explored for its potential therapeutic applications across various medical fields, including oncology, dermatology, hematology, virology, microbiology, and ophthalmology. The company emphasizes the importance of making these treatments safe, affordable, and accessible to patients globally, aiming to maximize their curative impact through diverse formulations and routes of administration.

The company is actively engaged in clinical trials to evaluate the efficacy and safety of its drug formulations, specifically PV-10 and PH-10, under the regulatory framework of the FDA's Investigational New Drug Application (IND) process. Provectus is committed to adhering to strict compliance with U.S. laws and regulations regarding unapproved drug products, highlighting the importance of conducting research within regulated clinical settings. This approach ensures that their innovative therapies are developed responsibly and ethically, ultimately aiming to provide effective treatment options for patients in need.

United States

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.

Provectus Pharmaceuticals

Company Details